Johnson & Johnson (JNJ) Cash & Equivalents Growth (5y) (2014 - 2026)

Johnson & Johnson (JNJ) Cash & Equivalents Growth (5y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn

Historic Data

Download Data
DateValue
Mar 29, 2026 11.35%
Dec 28, 2025 7.10%
Sep 28, 2025 -0.79%
Jun 29, 2025 10.70%
Mar 30, 2025 19.89%
Dec 29, 2024 6.85%
Sep 29, 2024 4.22%
Jun 30, 2024 11.59%
Mar 31, 2024 11.57%
Dec 31, 2023 3.84%
Oct 1, 2023 4.21%
Jul 2, 2023 3.81%
Apr 2, 2023 5.54%
Jan 1, 2023 -6.28%
Oct 2, 2022 -6.30%
Jul 3, 2022 -2.71%
Apr 3, 2022 -12.93%
Jan 2, 2022 -5.25%
Oct 3, 2021 -0.67%
Jul 4, 2021 -5.12%